SpePharm acquires major funding in new agreement
Amsterdam – Dutch specialty pharmaceutical company SpePharm (Amsterdam) has secured funds worth €26m after entering into a €10m revenue interest acquisition financing agreement with Paul Capital Healthcare. The cash injection will be used to fund SpePharm’s acquisition of the European rights for Procter & Gamble’s Dantrium, a treatment for malignant hyperthermia. At the same time, TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare closed a €16m equity financing round, and the company’s senior management will also participate in this current equity financing. The transactions will provide SpePharm with the resources to complete the build-up of its sales and marketing infrastructure, as well as aiding it to launch and promote its current product portfolio and acquire rights to additional products in
areas of therapeutic interest. Founded in 2006, SpePharm is focused on acquiring, registering and marketing specialty medicines essential for hospital markets. Its areas of therapeutic interest are mainly oncology, critical and supportive care. SpePharm focuses on therapeutic products with annual sales of under €100m.